Background Topical corticosteroids or six-food elimination diet is recommended as initial therapy for eosinophilic esophagitis (EoE). Aims We aimed to summarize published manuscripts that report outcomes of these therapies for EoE. Methods We performed a systematic review in MEDLINE, Web of Science, and Embase of published manuscripts describing topical fluticasone, topical budesonide, and sixfood elimination diet as therapies for EoE. We conducted meta-analysis of symptom improvement and the change in peak mucosal eosinophil count, with heterogeneity between studies examined with meta-regression analysis. Results Systematic review yielded 51 articles that met inclusion criteria. Summary histologic response rates were 68.3% [95% prediction limits (PL) 16.2-96.0%] for fluticasone, 76.8% (95% PL 36.1-95.1%) for budesonide, and 69.0% (95% PL 31.9-91.4%) for six-food elimination diet. Corresponding decreases in eosinophil counts were 37.8 (95% PL 19.0-56.7), 62.5 (95% PL 125.6 to -0.67, and 44.6 (95% PL 26.5-62.7), respectively. Symptom response rates were 82.3% (95% PL 68.1-91.1%), 87.9% (95% PL 42.7-98.6%), and 87.3% (95% PL 64.5-96.3%), respectively. Meta-regression analyses decreased the initially large estimate of residual heterogeneity and suggested differences in histologic response rate associated with study populations' baseline eosinophil count and age. Conclusions The literature describing topical corticosteroids and six-food elimination diet consists of small studies with diverse methods and population characteristics. Meta-analysis with meta-regression shows initial histologic and symptomatic response rates on the same order of magnitude for topical corticosteroids and six-food elimination diet, but heterogeneity of study designs prevents direct comparison of modalities.
Introduction
Eosinophilic esophagitis (EoE) is a clinicopathologic disease with a substantial healthcare burden [1, 2] . Clinical guidelines suggest patients diagnosed with EoE, defined as the failure of esophageal eosinophilia to resolve after effective acid suppression, should receive a therapy with the aim of decreasing mucosal eosinophil counts, and recommend either topical corticosteroids (tCS) or the sixfood elimination diet (SFED; removal of dairy, wheat, egg, soy, nuts, and seafood) as initial therapy [1, 3] . However, there are no studies that directly compare these two treatment modalities.
In addition to SFED, other dietary approaches have been examined for therapy of EoE [4] . A four-food elimination diet, elemental diet, and allergy-test targeted elimination diets have been studied. Swallowed topical ciclesonide has also been studied as an alternative tCS for EoE [5] . These treatments are not addressed in this manuscript because the Electronic supplementary material The online version of this article (doi:10.1007/s10620-017-4642-7) contains supplementary material, which is available to authorized users.
& Evan S. Dellon edellon@med.unc.edu meta-regression techniques used here require a large number of studies for each modality. Previously published systematic reviews and/or metaanalyses have considered tCS and SFED in isolation but have included studies that have been heterogeneous in design and outcomes [6] [7] [8] [9] [10] [11] [12] [13] . Novel meta-regression techniques are particularly useful in such cases, as they can explore the high residual heterogeneity reported as a limitation in prior metaanalyses describing dietary and steroid therapies [6] [7] [8] [9] [10] [11] [12] [13] . Such analysis can also give insight into differences in outcomes associated with study design or baseline population characteristics, but this has never been done for EoE. The most useful estimate for clinicians in describing a treatment to patients is its average effectiveness in a population of similar patients. The overall mean reported in classical fixed and random effects meta-analysis can produce biased estimates and erroneously narrow confidence intervals if there are systematic differences in populations or the treatments [14] , and this limitation can be addressed by meta-regression.
Aims
The aims of this study were: (1) to perform a systematic review of studies that describe SFED and tCS as therapies for EoE; (2) to describe design features, outcomes reported, and characteristics of study populations for all included studies; and (3) to perform stratified meta-analysis and meta-regression analysis on groups of included studies with similarly specified outcomes.
Methods
We performed a systematic review of published manuscripts describing topical fluticasone, topical budesonide, and SFED as therapies for EoE, in accordance with the PRISMA guidelines [15] . Our search strategy was developed in consultation with a dedicated research librarian with expertise in systematic review methods. We searched MEDLINE, Web of Science, and Embase databases using search settings and filters as described in Table 1 . The search was independently performed by two investigators (CCC and SE) who reviewed all titles and abstracts and selected articles for detailed review and data extraction. For meta-analysis, we selected articles from those included in the systematic review that reported the mean and standard deviation of eosinophil counts (eosinophils per highpowered field; eos/hpf) before and after treatment, or the proportion of patients with histologic response defined as a threshold of eos/hpf. We also performed meta-analyses of studies that reported the proportion of patients with improvement in symptoms or reported symptoms in a way that could be simplified into a dichotomous improvement variable (yes or no).
Heterogeneity between studies was examined in metaregression analysis. Potential meta-regression moderators were selected a priori based on potential importance in describing differences in study populations or methods, as well as their availability in published manuscripts. Moderators included were study design as trial or cohort, proportion of male subjects, mean age, proportion with a PPI trial or pH/impedance testing to diagnose EoE, proportion of subjects with prior therapy, whether maximum eosinophil counts were reported overall or in the distal esophagus, and baseline mean maximum eosinophil count. Quantifying studies' risk of bias was not attempted to be quantified because studies could be subject to bias in different directions, while adjustment for risk of bias would assume all bias was in the same direction. Moderators were significance-tested using a bootstrap permutation method to estimate p [16] . Moderators with individual two-sided p value less than 0.2 were included for iterative reverse selection by maximum p value with a criterion for retention of p less than 0.05. Meta-analyses were presented in forest plots. The summary estimate of the mean with 95% confidence limits was presented as a diamond, and the 95% prediction limits (PL) were presented as brackets with a dotted line. Prediction limits include estimated residual heterogeneity between studies in addition to sampling error of the overall mean [17] . For analyses with one or more statistically significant meta-regression moderators, the predicted mean at common values of the moderator was presented beneath the overall random effects estimate and the studies were sorted in forest plots by descending value of the most statistically significant moderator. If no moderator was statistically significant, the studies were ordered by publication date.
Data for meta-analysis were abstracted from study text, tables, and figures. Parameters of interest were obtained from figures when possible and when estimates of interest were not present in text or tables. The outcome of histologic response was specified in several different ways: as a threshold, as a difference, and as a ratio. For meta-analysis of the difference and ratio, studies that did not provide the eosinophil counts at baseline and follow-up were excluded. Meta-analysis and meta-regression models were fit using mixed-effects models with the Hodges estimator of betweenstudy variance. Statistical analysis was performed in R version 3.3.0 using the metafor package version 1.9 [18, 19] .
Results
The systematic review search in MEDLINE, Web of Science, and Embase databases yielded 1533 unique records ( Fig. 1 ). Of these, 193 full articles were considered pertinent based on the title or abstract, and 51 were selected for inclusion: 33 articles describing therapy with topical fluticasone , 17 articles describing therapy with topical budesonide [28, 32-34, 36, 44, 51, 53-62] , and 9 articles describing therapy with SFED [60, [63] [64] [65] [66] [67] [68] [69] [70] . Manuscripts started in year of publication in 2003 among studies of topical fluticasone, 2007 among studies of topical budesonide, and 2006 among studies of SFED. Four randomized trials described topical fluticasone therapy, five described topical budesonide therapy, and none described SFED ( Table 2) .
Histologic response was reported as a proportion under a threshold of eos/hpf in the largest subset of studies included in systematic review [21, 25, 30, 31, 37, 43, 45-48, 50, 52-57, 59-63, 65-70] . The most common threshold was 15 eos/hpf, though two studies used thresholds of near but not 15 eos/hpf and were included with an adjustment term for the difference of reported threshold from 15 [40, 46, 52, 57, 60, 62] . Without meta-regression moderators, the predicted overall mean proportion of patients with a threshold histologic response to topical fluticasone was 68.3% (95% PL 16.2-96.0%). Studies of topical fluticasone where diagnosis of EoE was confirmed for all subjects with a PPI trial or pH/Impedance testing had significantly higher proportions with histologic response (Fig. 2a) . The estimated proportion of patients with histologic response to topical budesonide was 76.8% (95% PL 36.1-95.1%) (Fig. 2b) . The estimated proportion of patients with histologic response to SFED was 69.0% (95% PL 31.9-91.4%). A significant meta-regression moderator was not identified in studies of threshold histologic response for SFED (Fig. 2c) .
A subset of studies that reported histologic response as the mean and standard deviations of eosinophils per HPF before and after treatment allowed meta-analysis of the mean difference [21, 30, 31, 37, 43, 45, 47, 48, 50, 53-56, 59, 60, 62, 63, 65-68, 70] . The mean difference before and after therapy with topical fluticasone was a decrease of 37.8 eosinophils per HPF (95% PL 19.0-56.7). No metaregression moderator was statistically significant for studies of mean difference of fluticasone (Fig. 3a) . The mean difference before and after therapy with topical budesonide was a decrease of 62.5 (95% PL 125.6 to -0.7). Studies of topical budesonide with a higher baseline peak eosinophil count per HPF had a significantly greater decrease in eosinophil count after treatment (Fig. 3b) . The mean difference before and after therapy with SFED was a decrease of 44.6 eosinophils per HPF (95% PL 26.5-62.7). As with studies of budesonide, studies of SFED with a higher baseline peak eosinophil count per HPF had a significantly greater decrease in eosinophil count before and after treatment (Fig. 3c) .
The subset of studies that reported individual peak eosinophil counts before and after treatment or the Pearson correlation coefficient between counts before and after treatment were included in a meta-analysis of the ratio of maximum esophageal eosinophils before treatment to the maximum after treatment [21, 30, 31, 37, 45, 47, 48, 50, 53, 54, 56, 59, 63, [65] [66] [67] . The mean ratio before and after therapy with topical fluticasone was 0.20 (95% PL 0.03-1.49), with topical budesonide was 0.11 (95% PL 0.01-0.87), and with SFED was 0.10 (95% PL 0.02-0.39). No meta-regression moderators were statistically significant in analyses of the mean ratio (Supplemental Fig. 1a-c) .
The literature describing symptom response from tCS and SFED partially overlaps with the literature describing histologic response [21-23, 27, 37, 39, 40, 45, 47, 54, 56, 62, 63, 65-68, 70] . The proportion of patients with symptom improvement was 82.3% (95% PL 68.1-91.1%) among studies of topical fluticasone. The proportion of patients with symptom improvement was 87.9% (95% PL 42.7-98.6%) among studies of topical budesonide. The proportion of patients with symptom improvement was 87.3% (95% PL 64.5-96.3%) among studies of SFED. No meta-regression moderators were statistically significant in analyses of the mean ratio (Fig. 4a-c) . , and six-food elimination diet (c) with additional study details and summary estimates with 95% prediction limits. Studies are sorted in order of the statistically significant meta-regression moderator or by year if no moderator was significant at a threshold p \ 0.05. Studies from systematic review that included the proportion of patients with response at a threshold of or near 15 eosinophils per high-power field without missing values for meta-regression variables were included 
Discussion
Current guidelines recommend that either tCS or dietary elimination, typically with SFED, is acceptable first-line treatments for EoE [1, 3] . There have been no clinical studies directly comparing these modalities, and metaanalyses to date have been performed for each of the treatments in isolation without meta-regression. We therefore performed a meta-analysis with meta-regression of studies that examined the effects of topical fluticasone, topical budesonide, and SFED on peak mucosal eosinophil count and symptom response, based on data derived from the most inclusive systematic review of studies of tCS and SFED for EoE to date. We found that patients treated with all three therapies generally had improvement in symptoms and reduction in mean eosinophil count, but substantial uncertainty remains about which is most effective. Meta-regression analysis techniques showed studies' methods and characteristics of study populations could explain some of the heterogeneity between studies and suggested differences in histologic response rate associated with study populations' baseline peak eosinophil counts and age. The clinical implications of this work are that topical fluticasone, topical budesonide, and SFED are generally effective treatments for eosinophilic esophagitis, and response rates are roughly of the same order of magnitude. It is premature to conclude, however, that one of these therapies is most effective for eosinophil counts or symptom improvement given the currently available literature, and given the overlap of wide probability limits between the different treatment modalities. Prior meta-analysis with classical methods and stringent criteria for study inclusion (primarily with RCTs) were well designed to show that tCS or SFED was effective for initial therapy of EoE in highly selected clinical trial populations [8, [11] [12] [13] . Our findings support these studies' conclusions, but caution the clinician that generalization of their estimates to particular populations that differ demographically or histologically from the included studies may not be appropriate.
We also found that there were substantial gaps in current knowledge describing EoE treatments. Only a few studies examined the effectiveness of maintenance therapy with a mucosal agent [25, 71, 72] . Very little is known about the longitudinal course of EoE patients under treatment, especially among patients on SFED, and what is known suggests relapse is common if treatments are stopped. Only two retrospective studies examined the effectiveness of second-line therapies, though at least a fifth to a third of patients fail to respond to first-line therapies [34, 51] .
Our study is limited in that we did not directly compare the results of our analyses between tCS and dietary elimination. Our findings show that such an analysis would be problematic because study outcomes seem to vary nonrandomly with factors other than the choice of therapy. For example, study results were correlated with subject age, baseline maximal eosinophil count, and the rigor of studies' diagnosis of EoE. In a direct comparison, it would be unclear whether outcomes differed because of effectiveness of the interventions or variability in these features. This study is also limited in that it provides no new primary data but rather summarizes and interprets existing literature. Additionally, the definition of symptom improvement varied widely between included studies, and this outcome is limited in that a standard symptom score is not reported in most of the studies. Conclusions about the effectiveness of SFED should be tempered by the absence of a randomized study and potential challenges of adherence to an elimination diet [73, 74] .
The strengths of the study include the rigorous and comprehensive systematic review, analysis of both threshold eosinophil count responses as well as absolute and relative change in counts, stratifying analysis by tCS type (fluticasone vs budesonide), and incorporating novel meta-regression methods. Moreover, we have included more studies and therefore more patients under treatment than other recent meta-analyses of EoE treatment.
In summary, this systematic review with meta-analysis using meta-regression techniques shows histologic response rates for tCS and SFED ranging from 68 to 77%, decreasing in eosinophil counts ranging from 38 to 63 eos/ hpf, and symptom responses of 82-88%. Future studies should compare therapies to one another in a randomized study design, report symptoms and endoscopic findings using validated instruments, and report mucosal response as the proportion of subjects with a total esophageal peak eosinophil count under 15 using a standard area of highpower field [75] . For this purpose, validated symptom scores are available for adults and children [76, 77] , and a standardized endoscopic findings score has emerged [78] . In addition, future studies should examine the durability of each therapy in maintaining remission and consider analyses stratified by baseline age and maximum eosinophil count. Until these data are available, the recommendation in guidelines that either dietary elimination or topical steroids could be considered as a first-line b Fig. 3 Mean difference for eosinophils before and after therapy in studies of topical fluticasone (a), topical budesonide (b), and six-food elimination diet (c) in order of publication date or, if present, selected meta-regression moderator. Studies are sorted in order of the statistically significant meta-regression moderator or by year if no moderator was significant at a threshold p \ 0.05. Studies from systematic review that included the mean and standard deviation of eosinophils per high-power field before and after therapy without missing values for meta-regression variables were included treatment for EoE after non-response to PPIs remains reasonable. The other authors have no potential conflicts related to this manuscript to report.
